Sacubitril
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Sacubitril: From Heart Failure to Diabetic Nephropathy
One-Sentence Summary
Sacubitril is the neprilysin-inhibitor component of the ARNI combination (sacubitril/valsartan), whose proven use is in heart failure with reduced ejection fraction (HFrEF). The TxGNN model’s five candidate indications include several that lack any biological plausibility, but diabetic nephropathy stands out as the only candidate supported by real evidence — 2 clinical trials (including a completed real-world study and a Phase 4 RCT in setup) and 20 publications, including a post-hoc analysis of the pivotal PARADIGM-HF trial.
Note on candidate selection: TxGNN’s raw top-ranked prediction (rank 1, “brain small vessel disease 1 with or without ocular anomalies,” score 99.58%) and three other candidates (ranks 2, 4, 5) have no clinical trials, no relevant literature, and no mechanistic link to neprilysin inhibition — the evidence pack itself flags these as likely embedding noise rather than genuine signal. This report therefore focuses on diabetic nephropathy (rank 3), the only candidate with a coherent mechanism and supporting data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Heart failure with reduced ejection fraction (HFrEF) — inferred from trial/literature context (e.g., NCT04735354, PARADIGM-HF); not formally recorded in this evidence pack |
| Predicted New Indication | Diabetic Nephropathy |
| TxGNN Prediction Score | 99.50% (rank 8,395 among all candidates) |
| Evidence Level | L3 (observational studies / post-hoc RCT analysis; no completed prospective RCT with renal endpoints) |
| India Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in this evidence pack (marked as a data gap). Based on known pharmacology, sacubitril is the prodrug component of the angiotensin receptor–neprilysin inhibitor (ARNI) combination sacubitril/valsartan, whose efficacy in HFrEF is well established (referenced within this pack via the PARADIGM-HF post-hoc analysis, PMID 29661699, and the India real-world HFrEF study NCT04735354).
Mechanistically, neprilysin inhibition raises circulating natriuretic peptides (ANP/BNP/CNP), which improve glomerular hemodynamics, reduce proteinuria, and exert anti-inflammatory and anti-fibrotic effects on the kidney. Combined with valsartan’s RAAS blockade, this dual action plausibly extends beyond cardiac benefit into renal protection — a rationale reinforced by multiple animal models of diabetic kidney disease (db/db mice, streptozotocin-induced diabetic rats) showing reduced glomerulosclerosis and oxidative stress with sacubitril/valsartan treatment.
Clinically, this is supported by a completed BOLD-MRI cohort study in type 2 diabetics (PMID 40416927) and a randomized human study in diabetic nephropathy patients with hypertension (PMID 37549515), plus an ongoing Phase 4 RCT (NCT06501651) specifically designed to compare sacubitril/valsartan against valsartan alone in type 2 diabetic nephropathy. However, no completed RCT with hard renal endpoints (eGFR decline, ESRD) yet exists — evidence remains at the observational/mechanistic tier.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06501651 | Phase 4 | Not yet recruiting | 297 | RCT comparing sacubitril/valsartan vs. valsartan in essential hypertension with type 2 diabetic nephropathy; 12-week treatment period, 2:1 randomization |
| NCT04735354 | N/A (observational) | Completed | 268 | Retrospective real-world EMR study of sacubitril/valsartan in HFrEF patients in India; supports safety/utilization pattern but not renal-specific |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37549515 | 2023 | RCT (human) | Int Immunopharmacol | 112 diabetic nephropathy + hypertension patients randomized to nifedipine + valsartan vs. nifedipine + sacubitril/valsartan; evaluated renal function outcomes |
| 29661699 | 2018 | Secondary analysis of RCT | Lancet Diabetes Endocrinol | Post-hoc analysis of PARADIGM-HF: neprilysin inhibition effect on renal function in T2DM patients with chronic heart failure on target RAAS-inhibitor doses |
| 40416927 | 2025 | Cohort (imaging) | Diabetes Metab Syndr Obes | BOLD-MRI study evaluating renal protective effects of sacubitril/valsartan in type 2 diabetics |
| 37625003 | 2023 | Review | Diabetes Care | Update on pillars of diabetic kidney disease therapy, including RAAS blockade and emerging agents |
| 34431635 | 2021 | Review | Rev Med Suisse | Potential role of sacubitril/valsartan in type 2 diabetes management, including glycemic and renal effects |
| 35165832 | 2022 | Review | Curr Hypertens Rep | Review of newer BP-lowering drugs targeting hypertensive target organ (including renal) damage |
| 35975848 | 2023 | Review | Curr Diabetes Rev | Cardiorenal complications of diabetes and novel combination therapies |
| 33870733 | 2021 | Animal study | Am J Physiol Renal Physiol | Differential effects of sacubitril/valsartan vs. valsartan on diabetic kidney disease in db/db and KKAy mice |
| 35992034 | 2022 | Animal study | Diabetes Metab Syndr Obes | Sacubitril/valsartan improves early diabetic nephropathy in rats via NLRP3 inflammasome inhibition |
| 37202215 | 2023 | Animal study | Nephrol Dial Transplant | Sacubitril/valsartan ameliorates renal tubulointerstitial injury via increased renal plasma flow in diabetic mice with aldosterone excess |
India Market Information
Sacubitril currently has no marketing authorization registered in India (0 licenses on file; market status: not marketed). No product-level dosage form or indication data is available.
Safety Considerations
Drug Interactions (from DDInter, 6 total, all Moderate severity):
| Interacting Drug | Interaction Level |
|---|---|
| Nitisinone | Moderate |
| Rosuvastatin | Moderate |
| Simvastatin | Moderate |
| Cobicistat | Moderate |
| Revefenacin | Moderate |
| Alpelisib | Moderate |
No package-insert-level warnings or contraindications were available in this evidence pack; please refer to the official product label for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale for renal protection is biologically sound and supported by consistent animal and early human data, but no completed prospective RCT with hard renal endpoints exists yet — the only purpose-built Phase 4 trial (NCT06501651) has not started recruiting. Evidence level L3 does not meet the bar for a Go or even a guarded proceed at this stage.
To proceed, the following is needed:
- Completion and results of NCT06501651 (Phase 4 RCT, sacubitril/valsartan vs. valsartan in T2DM nephropathy)
- Full mechanism-of-action documentation (currently a data gap, DG002)
- India-specific regulatory/label review, since the drug is not currently marketed there (DG001 — TFDA label warnings/contraindications required before any S1 safety screening)
- Renal-specific hard-endpoint data (eGFR slope, progression to ESRD) beyond the current surrogate/imaging and animal-model evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.